Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes by Kapitza, Christoph et al.
Oral Insulin: A Comparison With
Subcutaneous Regular Human Insulin in
Patients With Type 2 Diabetes
CHRISTOPH KAPITZA, MD
1
ERIC ZIJLSTRA, PHD
1
LUTZ HEINEMANN, PHD
1
M. CRISTINA CASTELLI, PHD
2
GARY RILEY, DVM, PHD
2
TIM HEISE, MD
1
OBJECTIVE — To determine the pharmacokinetic and pharmacodynamic properties of an
oral insulin (OI) formulation compared with subcutaneously injected regular human insulin
(RHI).
RESEARCH DESIGN AND METHODS — Ten male patients with type 2 diabetes
(means  SD; A1C 7.0  1.1%; BMI 28.3  2.7 kg/m
2) received either 300 units of insulin
combined with 400 mg of delivery agent orally or 15 units RHI subcutaneously under isogly-
cemic clamp conditions.
RESULTS — Maximum insulin concentration was greater and onset of action was faster with
OI (Cmax 93  71 vs. 33  11 U/ml; AUCGIR
(01h) 173  86 vs. 27  32 mg/kg; P  0.05).
Mean insulin concentration and glucose infusion rate returned to baseline within 3 h after OI
administration. Relative bioavailability of OI was 7  4% (1st 2 h).
CONCLUSIONS — This proof-of-concept study demonstrated that absorption of OI is fea-
sible under fasting conditions. OI has a fast onset and a short duration of action but also shows
a rather high between-subject variability in absorption.
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O
raladministrationofinsulinhasthe
potentialadvantageofamorephys-
iological action by its direct effect
on hepatic glucose production (1,2).
Thus far various oral insulin approaches
howeverhaveonlypartiallyproducedsat-
isfactory results (1,3,4). Gastrointestinal
absorption of insulin is hampered by fac-
tors such as enzymatic degradation and
lack of permeation through epithelial
cells (5). Noncovalent interaction of the
novel drug-carrier molecule monoso-
dium N-(4-chlorosalicyloyl)-4-aminobu-
tyrate(4-CNAB)withinsulinmightcreate
more favorable physico-chemical proper-
tiesforgastrointestinalinsulinabsorption
(6,7). In this study, 4-CNAB has been
combinedwithhumaninsulintofacilitate
gastrointestinal insulin absorption.
RESEARCH DESIGN AND
METHODS— A single-center, open-
label, randomized, two-period cross-
over, isoglycemic glucose clamp study
was used to determine the pharmacoki-
neticandpharmacodynamicpropertiesof
an oral insulin (OI) formulation with
4-CNAB compared with subcutaneous
regular human insulin (RHI). The proto-
col was approved by an independent eth-
ics committee and the study was
performed in accordance with the Decla-
rationofHelsinki.Atotalof14maleadult
patients diagnosed with type 2 diabetes
for over a year and without insulin ther-
apy were screened after providing written
informed consent (see all the inclusion
and exclusion criteria in the online appendix,
available at http://care.diabetesjournals.org/
cgi/content/full/dc09-1807/DC1). Ten
patients were enrolled. One patient with-
drew consent during the ﬁrst clamp visit
andwasreplaced,resultingintenpatients
(age 55  9 years [means  SD]; A1C
7.01.1%;BMI28.32.8kg/m
2)com-
pletingthestudy.Subjectsreceivedeither
300 units OI combined with 400 mg
4-CNABintwocapsules(eachcontaining
150 units OI plus 200 mg 4-CNAB) or a
subcutaneous injection of 15 units RHI
(Humulin R 100 units/ml; Eli Lilly, Indi-
anapolis, IN) on two separate dosing days
separated by 1–20 days. Patients did not
take oral hypoglycemic agents 24 h prior
to each dosing.
Glucose clamp procedure
Afteranovernightfast,patientswerecon-
nected to a Biostator (MTB Medizintech-
nik, Ulm, Germany). The clamp level, set
to the subject’s fasting blood glucose con-
centration, was established by intrave-
nous infusions of insulin (Actrapid; Novo
Nordisk, Bagsvaerd, Denmark) (0.2 mU  
kg
1 min
1from2hpredosinguntilthe
end of the experiment) and a variable in-
fusion of glucose. At t  0, one of the two
study medications was administered. The
pharmacokinetic (insulin levels) and
pharmacodynamic(glucoseinfusionrates
[GIRs])responsestothestudymedication
were measured for 6 h. The safety param-
eters studied included adverse events,
laboratory data, vital signs, physical ex-
aminations, and electrocardiograms.
Statistical analysis methods
Area under the curve for plasma insu-
lin concentration (AUCINS) and GIR
(AUCGIR) were calculated with the trape-
zoidal rule. Insulin and GIR values were
corrected for the baseline intravenous in-
sulininfusionbysubtractingthemeanin-
sulin concentrations or GIR in the last
hour before study drug administration
from all postdosing values. Individual
GIR proﬁles were then smoothed using a
polynomial function of the 6th order and
maximum GIR (GIRmax), time to GIRmax
(TGIRmax), time to half-maximum GIR be-
fore reaching GIRmax (TGIR-50%-early), and
time to half-maximum GIR after reaching
GIRmax (TGIR-50%-late) were calculated.
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were calculated as the dose-corrected ra-
tios of individual AUCs below insulin or
GIR proﬁles after oral and subcutaneous
application (8).
One subject was excluded from the
bioavailability and biopotency analysis
due to a very low pharmacokinetic and
metabolic response to RHI administra-
tion. In addition, two subjects with an
absent metabolic response to RHI admin-
istration in the 1st hour after application
were excluded from the biopotency anal-
ysisinthe0-1hperiod.Two-sidedsigned
Wilcoxon rank sum tests and Kruskal-
Wallis nonparametric tests were used for
comparisons between treatments. P 
0.05 was considered to be statistically
signiﬁcant.
RESULTS— Figure 1 shows the phar-
macokinetic (A) and pharmacodynamic
(B) responses to oral and subcutaneous
insulin administrations. All subjects
showed early enhanced pharmacokinetic
andpharmacodynamicresponsesafterOI
administration. Maximum plasma insulin
concentration (Cmax) was signiﬁcantly
higher (93  71 vs. 33  11 U/ml) and
time to Cmax (Tmax) was signiﬁcantly
shorter (27  9 vs. 161  83 min) with
OIadministration.Relativebioavailability
of OI for the 0-1 h, 0-2 h, and 0-6 h pe-
riods were 26  28%, 7  4%, and 2 
1%, respectively. Respective values for
biopotency were 55  92%, 12  9%,
and 3  1%.
Plasma C-peptide concentrations
showed no signiﬁcant increase in any of
the experiments and were not signiﬁ-
cantly different between the two treat-
ments.
No adverse events and no clinically
relevant changes in vital signs, electrocar-
diograms, or standard safety laboratory
parameters were observed.
CONCLUSIONS — This is the ﬁrst
glucose clamp study demonstrating that
OI is absorbed under fasting conditions
and exhibits early enhanced pharmacoki-
netic and pharmacodynamic responses.
The duration of action of OI was much
shorter than that of RHI with a return to
thebaselineeffectwithin2–3h.Nosafety
concernsarosefromthisshort-termstudy
with single dose administrations.
The fast pharmacokinetic and meta-
bolic time-proﬁles of OI observed in this
study may be advantageous in patients
with type 2 diabetes by restoring normal
ﬁrst phase insulin secretion (9) and po-
tentially leading to an improvement in
glycemiccontrol(10).OI’sonsetofaction
seems to be in the range of (or even faster
than) what is published for subcutaneous
fast–acting analogues (11), but a head-to-
head comparison has yet to be done. OI
should also have the advantage of reach-
ing the liver in high concentration
through the portal vein after gastrointes-
tinal absorption resulting in a more phys-
iological and stronger effect on hepatic
glucoseproductionandaweakereffecton
the peripheral tissues (potentially avoid-
ing hypoglycemia) than subcutaneous in-
sulin preparations.
In this small proof-of-concept study,
onlyarelativelysmallamount(7%forthe
2-h period after drug administration) of
OI is absorbed under fasting conditions
with an SD of 4%. Thus, variability in ab-
sorption (coefﬁcient of variation 60–
70%) is about as high for OI as that
reported for NPH insulin (11) but may
increasefurtherwithprandialadministra-
tion. Because of the narrow therapeutic
window for insulin, this high between-
subject variability might restrict clinical
use of OI to patients with a high endoge-
nous insulin secretion capacity. This ﬁrst
pilot study just provides a proof-of-
concept for OI under fasting conditions.
Additional investigations are therefore
needed in particular to determine the
pharmacodynamic (intraindividual) vari-
ability and the effect of food on oral insu-
lin absorption before longer-term studies
Figure 1—A: Pharmacokinetic (plasma insulin concentration) response to administration of an
oral insulin formulation (uninterrupted line) and subcutaneous regular human insulin (dotted
line)attime0h.PlasmainsulinconcentrationsarepresentedasmeansSEM.AUCINS
(01h):
2,559  1,831 vs. 542  296 U   min
1   ml
1, P  0.05, AUCINS
(06h): 3,225  2,320 vs.
7,0042,440U min
1 ml
1,P0.05.B:Pharmacodynamic(GIR)response.GIRsaregiven
for mean raw (thin line) and smoothed (bold line) data. AUCGIR
(01h): 173  86 vs. 27  32
mg/kg, P  0.05. AUCGIR
(02h): 297  143 vs. 137  107 mg/kg, P  0.05. AUCGIR
(06h):
(374135vs.651380mg/kg).TGIRmax:4016vs.255108min,P0.05.TGIR-50%-early:
136vs.15087min,P0.05.TGIR-50%-late:11579vs.360min,P0.05.GIRmax:4.4
2.2 vs. 3.6  1.8 mg   kg
1   min
1. sc, subcutaneous.
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